Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

Maria Buti, Scott Fung, Edward Gane, Nezam H. Afdhal, Robert Flisiak, Selim Gurel, John F. Flaherty, Eduardo B. Martins, Leland J. Yee, Phillip Dinh, Jeffrey D. Bornstein, G. Mani Subramanian, Harry L.A. Janssen, Jacob George, Patrick Marcellin

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Background: Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF. Methods: Patients enrolled in studies GS-US-174-0102 and GS-US-174-0103 who had baseline liver biopsy–diagnosed cirrhosis and entered the open-label phase of the studies were included in the virologic and serologic analyses. Patients (both HBeAg positive and negative) with paired liver biopsies at baseline and 5 years (N = 348) were included in a histologic analysis. Results: After 5 years on study, comparing patients with and without baseline cirrhosis, respectively: 99.2 and 98.0 % achieved virologic response (hepatitis B viral load < 69 IU/ml) (p = 0.686); 79.7 and 81.9 % had normal serum levels of alanine aminotransferase (p = 0.586); 4.0 and 1.2 % developed hepatocellular carcinoma (p = 0.044). In HBeAg-positive patients with and without baseline cirrhosis, HBsAg loss occurred in 14.4 and 8.3 % of patients, respectively (p = 0.188). One HBeAg-negative patient had HBsAg loss. Conclusions: This represents the largest analyses to date of CHB patients with sequential liver biopsies demonstrating that treatment with TDF for up to 5 years is associated with favorable virologic, serologic, and histologic outcomes, regardless of baseline cirrhosis status. Notably, histologic improvement was observed in the majority of cirrhotic and noncirrhotic patients.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalHepatology International
Issue number2
StatePublished - Apr 1 2015


  • Antiviral agent
  • Chronic hepatitis B
  • Cirrhosis
  • Hepatitis B e antigen
  • Hepatitis B surface antigen
  • Tenofovir disoproxil

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years'. Together they form a unique fingerprint.

Cite this